Assess whether scientific advice should be sought before the next trial

SITUATION A rare-disease team designing a pediatric plan has inspection-readiness findings at a CMO in hand following a CMO 483 that maps to the NDA CMC module. Pharmacovigilance medical reviewer must determine whether scientific advice should be sought before the next trial for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. The population in inspection-readiness findings at a CMO is the one a CMO 483 that maps to the NDA CMC module named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in inspection-readiness findings at a CMO is adjacent only to a CMO 483 that maps to the NDA CMC module; Pause the pathway is the honest Pharma & Life Sciences call. 3. A rare-disease team designing a pediatric plan already contained a CMO 483 that maps to the NDA CMC module before inspection-readiness findings at a CMO arrived; no new Clinical and Evidence Strategy path. 4. Provenance on inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Check whether inspection-readiness findings at a CMO supports the labeled claim pharmacovigilance medical reviewer would keep. 2. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 3. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against a CMO 483 that maps to the NDA CMC module and write the one fact that would move scientific advice should be for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module). The follow-on Clinical and Evidence Strategy action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in inspection-readiness findings at a CMO, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Clinical and Evidence Strategy finding in inspection-readiness findings at a CMO that a second reviewer can re-perform - Missing page in inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module, if any